TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11054434
Drug: Surface area-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surface area-based dosing
Study: 8972014
Drug: Clopidogrel at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel at doses of 10, 25, 50, 75 or 100 mg OD
Study: 8972014
Drug: Ticlopidine 250
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 250 mg BID
Study: 1738517
Drug: Hydrogel pessary
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel pessary containing 10 mg of prostaglandin E2
Study: 6824553
Drug: mianserin 30
Normalized name: mianserin 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin 30 mg at night
Study: 28929669
Drug: Modified Chaiping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Chaiping decoction (6 doses per week, one dose every day in two times by oral administration)
Study: 25081808
Drug: Daily weight
Normalized name: Thrifty White One Daily Weight Control Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily weight tracking for 6 months
Study: 25081808
Drug: Weekly weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly weight tracking for 6 months
Study: 22539020
Drug: Sibutramine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (15 mg daily for 12 weeks)
Study: 14747389
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg folic acid
Study: 14747389
Drug: High-dose folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose folic acid (all groups combined)
Study: 11259518
Drug: Coping skills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping skills intervention (daily practice with audiotaped instructions)
Study: 9676351
Drug: Bronchoretard Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchoretard Capsules
Study: 9676351
Drug: Capsule formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulation from the US market
Study: 7990375
Drug: Veroshpiron (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veroshpiron (50-100 mg/day)
Study: 18250489
Drug: Taliton (carvedilol)
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taliton (carvedilol) starting dose 3.125 mg twice daily, increased to target dose 25 mg twice daily over 6 months
Study: 15564697
Drug: Bepridil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil (200 mg/day)
Study: 15564697
Drug: Bepridil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil (200 mg/day) + Aprindine (40 or 60 mg/day)
Study: 10365144
Drug: Chemo-immunotherapy including
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-immunotherapy including interferon-alpha 2a, interleukin-2, 5-fluorouracil (5-FU), isotretinoin (ISO), and vinblastin (VBL)
Study: 1967561
Drug: Xamoterol 200
Normalized name: xamoterol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol 200 mg b.i.d. for 3 months
Study: 1967561
Drug: Digoxin 0.125
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.125 mg b.i.d.
Study: 29343201
Drug: Blackcurrant juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blackcurrant juice (500 mg of polyphenols)
Study: 28825235
Drug: Ethyl chloride
Normalized name: Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl chloride aerosol spray (n=66)
Study: 28825235
Drug: Placebo aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo aerosol spray (n=60)
Study: 26074365
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) administered through a buccal window approach
Study: 26074365
Drug: Conventional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional management via creation of a window on the buccal wall and curettage of the walls of the defect
Study: 25309087
Drug: Aconite cake‐separated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aconite cake‐separated moxibustion (1 cone, 3 treatments/week)
Study: 25309087
Drug: Aconite cake‐separated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aconite cake‐separated moxibustion (2 cones, 3 treatments/week)
Study: 25309087
Drug: Aconite cake‐separated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aconite cake‐separated moxibustion (1 cone, 6 treatments/week)
Study: 25309087
Drug: Aconite cake‐separated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aconite cake‐separated moxibustion (2 cones, 6 treatments/week)
Study: 21247664
Drug: Biafine Topical
Normalized name: Biafine Topical Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biafine Topical Emulsion (BTE)
Study: 15117996
Drug: Acupuncture twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture twice per week for 4 weeks
Study: 3475231
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg or 2 mg PGE2 intravaginally at an interval of 6 hours
Study: 3475231
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin and amniotomy
Study: 2129320
Drug: pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin 20 mg b.i.d.
Study: 2129320
Drug: cholestyramine 16‐24
Approvals — FDA: no, EMA: no, PMDA: no
Description: cholestyramine 16‐24 g/day
Study: 973981
Drug: Diazepam (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5-10 mg three times daily)
Study: 973981
Drug: Thioridazine (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (25-50 mg three times daily)
Study: 27842179
Drug: Sacubitril/Valsartan 97/103
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/Valsartan 97/103 mg twice daily
Study: 27842179
Drug: Sacubitril/Valsartan 97/103
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/Valsartan 97/103 mg twice daily (newly started MRA)
Study: 27842179
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg twice daily (newly started MRA)
Study: 26291258
Drug: Triamcinolone hexacetonide
Normalized name: Triamcinolone Hexacetonide
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone hexacetonide (20mg/ml)
Study: 21784746
Drug: Standard arrhythmia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard arrhythmia detection and therapy approaches (Control group)
Study: 16565252
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (EPO) treatment to normalize hemoglobin (Hgb) levels.
Study: 16565252
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (EPO) treatment to achieve Hgb >12 g/dl.
Study: 16565252
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (EPO) treatment to achieve Hgb >11 g/dl.
Study: 16565252
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (EPO) treatment for normalization of hematocrit.
Study: 16565252
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (EPO) treatment.
Study: 3774016
Drug: Adjuvant combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant combination chemotherapy with low-dose prednisone (7.5 mg/day) and CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
Study: 3774016
Drug: CMFp +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMFp + T (chemotherapy plus low-dose prednisone and tamoxifen)
Study: 3774016
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone (p + T)
Study: 3774016
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment after total mastectomy and axillary clearance (observation group)
Study: 28815256
Drug: Ibuprofen capsules
Normalized name: Diphenhydramine Hydrochloride and Ibuprofen Capsules
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen capsules
Study: 25661407
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with high Lp(a) concentrations (>500 mg/L) in the intervention group
Study: 18204335
Drug: Aripiprazole (initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (initiated at 10 mg/d, flexibly dosed at 5-30 mg/d)
Study: 16728480
Drug: Concurrent radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent radiochemotherapy (RT-CT) - two cycles of platinum etoposide followed by two cycles of platinum-vinorelbine
Study: 16728480
Drug: Sequential radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential radiochemotherapy (RT-CT) - three cycles of chemotherapy followed by radiotherapy
Study: 9892032
Drug: HFA-134a albuterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-134a albuterol sulfate (108 microg of albuterol sulfate, equivalent to 90 microg of albuterol base)
Study: 9892032
Drug: CFC albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFC albuterol (equivalent doses)
Study: 2363736
Drug: Low-dose fish
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fish oil (27 mg/kg EPA and 18 mg/kg DHA)
Study: 2363736
Drug: High-dose fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fish oil (54 mg/kg EPA and 36 mg/kg DHA)
Study: 2363736
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (low-dose, high-dose, and olive oil)
Study: 26725184
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg orally daily on days 2-16) plus Carboplatin (AUC=5 on day 1) and Paclitaxel (200 mg/m2 intravenously on day 1) followed by Erlotinib (150 mg orally)
Study: 25332253
Drug: Proton radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton radiotherapy with chemotherapy (vincristine, actinomycin, and cyclophosphamide or vincristine, actinomycin, and ifosfamide)
Study: 25332253
Drug: Proton radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton radiotherapy with chemotherapy
Study: 12003920
Drug: Non-at-risk drinkers
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-at-risk drinkers in occupational medicine vs. primary care
Study: 12003920
Drug: At-risk drinkers
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: At-risk drinkers in occupational medicine vs. primary care
Study: 7886126
Drug: Erythromycin estolate
Normalized name: Erythromycin Estolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin estolate (1000 mg twice daily)
Study: 7886126
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate (1500 mg daily, 50% higher than erythromycin estolate)
Study: 2219563
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (lidocaine-prilocaine), applied for 60 minutes
Study: 2219563
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (lidocaine-prilocaine), applied for over 90 minutes
Study: 26044714
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of touch and vision
Study: 24522442
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg DHA/d (treatment)
Study: 15182773
Drug: Carvedilol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (target 25 mg bid)
Study: 15182773
Drug: Enalapril (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (target 10 mg bid)
Study: 15182773
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of carvedilol and enalapril
Study: 15182773
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (combination, carvedilol, enalapril)
Study: 1907432
Drug: 20 infusions
Normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 infusions of Na2EDTA
Study: 1907432
Drug: 20 infusions
Normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 infusions of saline
Study: 6135253
Drug: Beta-blockade maintained
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockade maintained with 100 mg metoprolol per os two hours before surgery
Study: 27122150
Drug: Retinyl palmitate
Normalized name: Retinyl palmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinyl palmitate supplementation (25,000 IU daily)
Study: 15730048
Drug: Dipyridamole 5
Normalized name: dipyridamole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 5 mg/kg
Study: 12517683
Drug: GRD 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRD 360 mg administered once-daily at bedtime (10 PM)
Study: 12517683
Drug: GRD 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRD 240 mg and higher administered once-daily at bedtime
Study: 12517683
Drug: All GRD
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All GRD groups (including 540 mg and 240 mg)
Study: 12517683
Drug: GRD 540
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRD 540 mg administered once-daily at bedtime
Study: 12517683
Drug: GRD 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRD 360 mg administered once-daily at 8 AM
Study: 9402265
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of daily GnRHa injections for 15 days after HCG administration
Study: 9402265
Drug: Disruption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disruption of daily GnRHa injections at the day of HCG administration
Study: 8228208
Drug: Lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10 mg once a day)
Study: 8228208
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amlodipine and lisinopril (once a day)
Study: 3943269
Drug: Nalmefene 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 6 mg
Study: 3943269
Drug: Nalmefene 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 12 mg
Study: 3943269
Drug: Nalmefene 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 24 mg
Study: 3943269
Drug: Nalmefene (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene (all doses)
Study: 26558919
Drug: Urinary iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urinary iodine excretion
Study: 16077402
Drug: High tidal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tidal volume/low positive end-expiratory pressure (10-12 mL/kg and 2-3 cm H2O)
Study: 16077402
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume/high positive end-expiratory pressure (8 mL/kg and 10 cm H2O)
Study: 8745670
Drug: Granisetron (G)
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron (G) 3 mg intravenously before chemotherapy
Study: 8745670
Drug: Ondansetron (O)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron (O) 8 mg intravenously, followed by 8 mg orally every eight hours for the next three days
Study: 6753090
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg naproxen administered as a single dose at night
Study: 6753090
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg naproxen administered twice daily
Study: 23574579
Drug: LMWH followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LMWH followed by warfarin (INR of 2.0-3.0)
Study: 21507585
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch plus bupropion
Study: 19585106
Drug: Citalopram (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (selective serotonin reuptake inhibitor) for 7-10 days
Study: 17763613
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with fractional resurfacing and ALA-PDT
Study: 14994406
Drug: 5% ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% ibuprofen cream applied in a 10-cm strip tid for 7 days (approximately 200 mg ibuprofen per strip)
Study: 14994406
Drug: 5% ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% ibuprofen cream
Study: 9481194
Drug: Intrapartum amnioinfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapartum amnioinfusion (AI) with 0.9% normal saline at 15 ml/min until a volume of 11 was completed, repeated if delivery did not occur within 4 hours.
Study: 7993831
Drug: granisetron 1
Normalized name: granisetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: granisetron 1 mg bd orally for 7 days
Study: 7993831
Drug: granisetron 1
Normalized name: granisetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: granisetron 1 mg bd orally for 7 days plus prophylactic dexamethasone (12 mg i.v.) on the first day only
Study: 7993831
Drug: metoclopramide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide (3 mg/kg i.v. loading dose; 4 mg/kg i.v. infusion) plus dex (12 mg i.v.) on the first day followed by met 10 mg orally tds for a further 6 days
Study: 2544431
Drug: Itraconazole capsules
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole capsules (50 mg)
Study: 2544431
Drug: Itraconazole capsules
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole capsules (100 mg)
Study: 2544431
Drug: Itraconazole capsules
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole capsules (200 mg)
Study: 2544431
Drug: Itraconazole capsules
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole capsules (100 mg) after 15 days
Study: 29664999
Drug: Fibrin sealant
Normalized name: FIBRIN SEALANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin sealant patch (patch group)
Study: 29664999
Drug: No patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: No patch (control group)
Study: 26141683
Drug: FOLFIRI-cetuximab followed
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FOLFIRI-cetuximab followed by oxaliplatin-based second-line chemotherapy with bevacizumab (Arm A)
Study: 26141683
Drug: OPTIMOX-bevacizumab followed
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: OPTIMOX-bevacizumab followed by irinotecan-based second-line chemotherapy with bevacizumab and anti-EGFR monoclonal antibody (Arm B)
Study: 21139151
Drug: Candidate vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidate vaginal microbicide gel containing cellulose acetate 1,2‐benzenedicarboxylate in a glycerol‐based vehicle
Study: 21139151
Drug: Candidate vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidate vaginal microbicide gel
Study: 16832124
Drug: Co-amoxiclav (antibiotics)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (antibiotics) administered on the day before and the day of embryo transfer
Study: 8900553
Drug: Methotrexate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (50 mg per m2) + Misoprostol (800 micrograms)
Study: 8900553
Drug: Misoprostol (vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (vaginal administration)
Study: 1797509
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and Glyburide (IG)
Study: 1797509
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and Placebo (IP)
Study: 21390173
Drug: Adenosine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (80 µg/kg/min)
Study: 19433134
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (combined mechanical vibrations, continuous passive motion, and thermotherapy)
Study: 15471073
Drug: GnRHa therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa therapy with 15 microg of diluted buserelin acetate given once a day intranasally
Study: 15471073
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 50 mg daily by oral administration
Study: 11327741
Drug: Long-chain triglycerides
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-chain triglycerides (LCTs) infusion
Study: 1064903
Drug: Liquid antacid
Normalized name: GNP Liquid Antacid Maximum Strength 400mg-400mg-40mg/5ml Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid antacid co-administered with ferrous salts (carbonate, fumarate, sulphate)
Study: 1064903
Drug: Ferrous carbonate
Normalized name: ferrous carbonate
DrugBank: Ferrous carbonate (DB13698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous carbonate with liquid antacid
Study: 29049382
Drug: Phone-based unannounced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phone-based unannounced pill counts in START (Lesotho)
Study: 29049382
Drug: Phone-based unannounced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phone-based unannounced pill counts in ENRICH (Ethiopia)